Because resistance to AR-targeted therapies is driven, in part, by cellular plasticity, we posit that DNMTs could serve as potentially actionable targets to limit therapy-driven cellular plasticity in prostate cancer. The gene discussed is AR; the disease is prostate carcinoma.